Altre lingue Hansa Biopharma AB

Azioni

HNSA

SE0002148817

Biotecnologia

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 17/04/2026			Variaz. 5gg	Var. 1 gen.
29,04 ^SEK	-0,41%		-5,47%	-15,48%

27/03	Adrigo Small & Midcap L/S cede il 10,97% a febbraio - contributo negativo da Online Brands	FW
24/03	Redeye: il nuovo finanziamento di Hansa Biopharma riduce il profilo di rischio dell'investimento	FW

Altre lingue

08/04	Hansa Biopharma to host Q1 2026 interim results conference call
26/03	Hansa Biopharma publishes 2025 Annual and Sustainability Reports
20/03	Hansa Biopharma Enters $30 Million Convertible Note Purchase Deal
20/03	Hansa Biopharma enters $30 million convertible loan agreement with Athyrium
16/03	Hansa Biopharma presenting at Redeye Theme Event, Commercialization in Life Science
13/03	Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science
10/03	Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026
09/03	Hansa Biopharma participating at Leerink Global Healthcare Conference
09/03	Hansa Biopharma participating at LSX Investival Showcase USA
06/03	Hansa Biopharma participating at Leerink Global Healthcare Conference
05/03	Hansa Biopharma Secures Action Date for US FDA Approval of Imlifidase
04/03	Hansa Biopharma says PDUFA action date for Imlifidase BLA set for December 19, 2026
04/03	PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
04/03	Food and Drug Administration Notifies Hansa Biopharma AB for Imlifidase
23/02	Hansa Biopharma presenting at TD Cowen's 46th Annual Health Care Conference
19/02	US FDA Accepts Hansa Biopharma's Imlifidase License Application
18/02	Hansa Biopharma : Biologics License Application (BLA) for imlifidase accepted by the FDA
18/02	Hansa Biopharma says co's biologics license application (BLA) for imlifidase accepted by the FDA
18/02	Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
18/02	Hansa Biopharma Ab's Biologics License Application for Imlifidase Accepted by the Fda
12/02	Hansa Biopharma (Q4 update): Strong Quarter in Europe
11/02	Hansa Biopharma : 11 Feb 2026 - Year-End Report January-December 2025 Presentation
11/02	Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
11/02	Hansa Biopharma board proposes that no dividend will be paid for 2025
11/02	Hansa Biopharma : 11 Feb 2026 - Year-End Report January-December 2025 Report